Monday.com Stock Tumbles on Disappointing Outlookby Mark Eisenberg 12.02.2024Monday.com stock (MNDY) fell 14.5% in pre-market trading following its weak Q4 results. Despite challenges, management remains confident in maintaining ...
Ethereum Breakout Watch: $3,000 on Horizon?by John Darbie 12.02.2024Ethereum's steady growth has analysts predicting it could reach $3,000 as it approaches a resistance level. However, there may be ...
Michelin Navigates Challenges, Eyes Bright Futureby Mark Eisenberg 12.02.2024Michelin reports flat earnings for 2023 with a net profit of €1.98 billion and a slight decrease in sales. However, ...
Dogecoin’s Price Potential: Breakout or Breakdown?by John Darbie 12.02.2024Dogecoin, the largest meme coin, could break out of its trading range with support at $0.075 and resistance at $0.088. ...
VF Corp Stock Surges Amid CEO Buy & Activist Pressureby Terry Bingman 12.02.2024VF Corp. saw its stock soar 13% on positive news amidst activist investor pressure. CEO's stock purchase and support from ...
Exciting Development: VF Stock Soars 12% with Founder’s Family Backingby Terry Bingman 12.02.2024Activist investor Engaged Capital gains support from VF's founding family, causing stock surge by 12% and boosting investor sentiment. VF ...
Spectral AI: Surgeon Appointment Boosts Boardby Lilu Anderson 12.02.2024Spectral AI has appointed Dr. J. Michael DiMaio to its Board of Directors as a non-executive member. This move strengthens ...
Lacoste Ropes In Finance Pro Philippe Gautierby Mark Eisenberg 12.02.2024Lacoste has appointed Philippe Gautier as their new EVP of Global Finance. Gautier's extensive experience in fashion finance and operations ...
Presto Automation $6M Financing Successby Terry Bingman 12.02.2024Presto Automation secures $6 million in financing, led by current investors. Company's AI Voice product shows significant growth. Court upholds ...
AN2 Therapeutics Phase 3 Trial Pause Impacts Stockby Mark Eisenberg 12.02.2024AN2 Therapeutics' stock rating was downgraded by Oppenheimer after pausing its Phase 3 trial. The company is reassessing and discussing ...